Literature DB >> 31129768

PD-L1 is a double-edged sword in colorectal cancer: the prognostic value of PD-L1 depends on the cell type expressing PD-L1.

Hsiang-Ling Ho1,2, Teh-Ying Chou1,2,3, Shung-Haur Yang4,5,6, Jeng-Kai Jiang4,5, Wei-Shone Chen4,5, Yee Chao7,4, Hao-Wei Teng8,9,10.   

Abstract

PURPOSE: To investigate the associations between programmed cell death ligand-1 (PD-L1) on tumor cells (TCs) or PD-L1 on tumor-infiltrating immune cells (TIICs) and the microsatellite instability (MSI) status in colorectal cancer (CRC).
METHODS: In total, 238 CRC patients were enrolled. PD-L1 expression and MSI status were studied by immunohistochemical staining and polymerase chain reaction. The χ2 test was used to compare characteristics. The Kaplan-Meier method was used for survival analysis. Cox proportional hazards models were used to determine the prognostic influence of clinicopathological factors.
RESULTS: Eighteen patients (7.6%) were had MSI-high (MSI-H) CRC. The number of patients with PD-L1 expression on TCs, stromal TIICs and intraepithelial TIICs was 13 (5.5%), 64 (26.9%) and 45 (18.9%), respectively. The MSI-H phenotype was significantly associated with younger age, right sidedness, mucinous component, high grade, stromal TIICs expressing PD-L1 (P = 0.042) and intraepithelial TIICs expressing PD-L1 (P < 0.001), but not TCs expressing PD-L1. PD-L1-expressing TCs were an independent marker of poor prognosis [hazard ratio (HR) = 3.387, P = 0.003], and PD-L1-expressing stromal TIICs were an independent marker of good prognosis (HR = 0.551, P < 0.001).
CONCLUSIONS: PD-L1-expressing TCs were a marker of poor prognosis; in contrast, PD-L1-expressing TIICs were a marker of good prognosis. The MSI-H phenotype was associated with the presence of PD-L1-expressing TIICs, but not of PD-L1-expressing TCs.

Entities:  

Keywords:  Colorectal cancer; Immunotherapy; Microsatellite instability; PD-L1

Mesh:

Substances:

Year:  2019        PMID: 31129768     DOI: 10.1007/s00432-019-02942-y

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  7 in total

1.  A Genetic Variant in CD274 Is Associated With Prognosis in Metastatic Colorectal Cancer Patients Treated With Bevacizumab-Based Chemotherapy.

Authors:  Wan Qin; Ben Zhao; Duanrui Wang; Jiamin Liu; Yilu Zhou; Wenjun Zhu; Yongbiao Huang; Hong Qiu; Xianglin Yuan
Journal:  Front Oncol       Date:  2022-06-28       Impact factor: 5.738

Review 2.  The clinical and prognostic significance of CMTM6/PD-L1 in oncology.

Authors:  Mahmoud Mohammad Yaseen; Nizar Mohammad Abuharfeil; Homa Darmani
Journal:  Clin Transl Oncol       Date:  2022-03-12       Impact factor: 3.340

3.  CMTM6 and PD-L1 coexpression is associated with an active immune microenvironment and a favorable prognosis in colorectal cancer.

Authors:  Qi-Hua Peng; Chun-Hua Wang; Hong-Min Chen; Rong-Xin Zhang; Zhi-Zhong Pan; Zhen-Hai Lu; Gao-Yuan Wang; Xin Yue; Wenlin Huang; Ran-Yi Liu
Journal:  J Immunother Cancer       Date:  2021-02       Impact factor: 13.751

4.  An exploration of immunohistochemistry-based prognostic markers in patients undergoing curative resections for colon cancer.

Authors:  Astrid Louise Bjørn Bennedsen; Luyi Cai; Rune Petring Hasselager; Aysun Avci Özcan; Khadra Bashir Mohamed; Jens Ole Eriksen; Susanne Eiholm; Michael Bzorek; Anne-Marie Kanstrup Fiehn; Thomas Vauvert F Hviid; Ismail Gögenur
Journal:  BMC Cancer       Date:  2022-01-14       Impact factor: 4.430

5.  Prognostic significance of CD163+ tumor-associated macrophages in colorectal cancer.

Authors:  Tao Xue; Kejing Yan; Yiqi Cai; Jiancheng Sun; Zhejing Chen; Xiaolei Chen; Wenyi Wu
Journal:  World J Surg Oncol       Date:  2021-06-24       Impact factor: 2.754

6.  Loss of survival advantage for deficient mismatch repair in patients with advanced colorectal cancer may be caused by changes in prognostic value of CD8+T cell.

Authors:  Bingyan Wang; Fei Li; Limei Guo; Siyi Lu; Junren Ma; Yanpeng Ma; Yan Meng; Junwei Wang; Xin Zhou; Wei Fu
Journal:  World J Surg Oncol       Date:  2020-08-07       Impact factor: 2.754

7.  Combined vaccine-immune-checkpoint inhibition constitutes a promising strategy for treatment of dMMR tumors.

Authors:  Inken Salewski; Steffen Kuntoff; Andreas Kuemmel; Rico Feldtmann; Stephan B Felix; Larissa Henze; Christian Junghanss; Claudia Maletzki
Journal:  Cancer Immunol Immunother       Date:  2021-04-18       Impact factor: 6.968

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.